GSK3 inhibition rescues growth and telomere dysfunction in dyskeratosis congenita iPSC-derived type II alveolar epithelial cells

Abstract

Dyskeratosis congenita (DC) is a rare genetic disorder characterized by deficiencies in telomere maintenance leading to very short telomeres and the premature onset of certain age-related diseases, including pulmonary fibrosis (PF). PF is thought to derive from epithelial failure, particularly that of type II alveolar epithelial (AT2) cells, which are highly dependent on Wnt signaling during development and adult regeneration. We use human iPSC-derived AT2 (iAT2) cells to model how short telomeres affect AT2 cells. Cultured DC mutant iAT2 cells accumulate shortened, uncapped telomeres and manifest defects in the growth of alveolospheres, hallmarks of senescence, and apparent defects in Wnt signaling. The GSK3 inhibitor, CHIR99021, which mimics the output of canonical Wnt signaling, enhances telomerase activity and rescues the defects. These findings support further investigation of Wnt agonists as potential therapies for DC related pathologies.

Data availability

Sequencing data was deposited in GEO: GSE160871

The following data sets were generated

Article and author information

Author details

  1. Rafael Jesus Fernandez III

    Medical Scientist Training Program, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9295-4810
  2. Zachary J G Gardner

    Medical Scientist Training Program, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  3. Katherine J Slovik

    Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  4. Derek C Liberti

    Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2991-9283
  5. Katrina N Estep

    Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  6. Wenli Yang

    Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  7. Qijun Chen

    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  8. Garrett T Santini

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  9. Javier V Perez

    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  10. Sarah Root

    College of Arts and Sciences and Vagelos Scholars Program, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  11. Ranvir Bhatia

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  12. John W Tobias

    Penn Genomic Analysis Core, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  13. Apoorva Babu

    Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  14. Michael P Morley

    Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  15. David B Frank

    Penn-CHOP Lung Biology Institute, Children's Hospital of Philadelphia, Philadelphia, United States
    Competing interests
    No competing interests declared.
  16. Edward E Morrisey

    Institute for Regenerative Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    Edward E Morrisey, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5785-1939
  17. Christopher J Lengner

    Department of Biomedical Sciences, University of Pennsylvania, Philadelphia, United States
    For correspondence
    lengner@vet.upenn.edu
    Competing interests
    No competing interests declared.
  18. F Brad Johnson

    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, United States
    For correspondence
    johnsonb@pennmedicine.upenn.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7443-7227

Funding

National Institute on Aging (R21AG054209)

  • Christopher J Lengner
  • F Brad Johnson

National Institute on Aging (5T32AG000255)

  • Rafael Jesus Fernandez III

Team Telomere/Penn Orphan Disease Center

  • Christopher J Lengner
  • F Brad Johnson

National Heart, Lung, and Blood Institute (R01HL148821)

  • Christopher J Lengner
  • F Brad Johnson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Fernandez et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,726
    views
  • 350
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

Share this article

https://doi.org/10.7554/eLife.64430

Further reading

    1. Stem Cells and Regenerative Medicine
    Sujeethkumar Prithiviraj, Alejandro Garcia Garcia ... Paul E Bourgine
    Research Article

    Tissue engineering strategies predominantly rely on the production of living substitutes, whereby implanted cells actively participate in the regenerative process. Beyond cost and delayed graft availability, the patient-specific performance of engineered tissues poses serious concerns on their clinical translation ability. A more exciting paradigm consists in exploiting cell-laid, engineered extracellular matrices (eECMs), which can be used as off-the-shelf materials. Here, the regenerative capacity solely relies on the preservation of the eECM structure and embedded signals to instruct an endogenous repair. We recently described the possibility to exploit custom human stem cell lines for eECM manufacturing. In addition to the conferred standardization, the availability of such cell lines opened avenues for the design of tailored eECMs by applying dedicated genetic tools. In this study, we demonstrated the exploitation of CRISPR/Cas9 as a high precision system for editing the composition and function of eECMs. Human mesenchymal stromal/stem cell (hMSC) lines were modified to knock out vascular endothelial growth factor (VEGF) and Runt-related transcription factor 2 (RUNX2) and assessed for their capacity to generate osteoinductive cartilage matrices. We report the successful editing of hMSCs, subsequently leading to targeted VEGF and RUNX2-knockout cartilage eECMs. Despite the absence of VEGF, eECMs retained full capacity to instruct ectopic endochondral ossification. Conversely, RUNX2-edited eECMs exhibited impaired hypertrophy, reduced ectopic ossification, and superior cartilage repair in a rat osteochondral defect. In summary, our approach can be harnessed to identify the necessary eECM factors driving endogenous repair. Our work paves the road toward the compositional eECMs editing and their exploitation in broad regenerative contexts.

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine
    Joshua G Medina-Feliciano, Griselle Valentín-Tirado ... José E Garcia-Arraras
    Research Article

    In holothurians, the regenerative process following evisceration involves the development of a ‘rudiment’ or ‘anlage’ at the injured end of the mesentery. This regenerating anlage plays a pivotal role in the formation of a new intestine. Despite its significance, our understanding of the molecular characteristics inherent to the constituent cells of this structure has remained limited. To address this gap, we employed state-of-the-art scRNA-seq and hybridization chain reaction fluorescent in situ hybridization analyses to discern the distinct cellular populations associated with the regeneration anlage. Through this approach, we successfully identified 13 distinct cell clusters. Among these, two clusters exhibit characteristics consistent with putative mesenchymal cells, while another four show features akin to coelomocyte cell populations. The remaining seven cell clusters collectively form a large group encompassing the coelomic epithelium of the regenerating anlage and mesentery. Within this large group of clusters, we recognized previously documented cell populations such as muscle precursors, neuroepithelial cells, and actively proliferating cells. Strikingly, our analysis provides data for identifying at least four other cellular populations that we define as the precursor cells of the growing anlage. Consequently, our findings strengthen the hypothesis that the coelomic epithelium of the anlage is a pluripotent tissue that gives rise to diverse cell types of the regenerating intestinal organ. Moreover, our results provide the initial view into the transcriptomic analysis of cell populations responsible for the amazing regenerative capabilities of echinoderms.